Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Vasc Interv Radiol. 2016 Dec 9;28(2):231–237.e2. doi: 10.1016/j.jvir.2016.09.022

Figure 3.

Figure 3

Propensity score-matched survival analysis of Medicare HCC patients only receiving TACE compared with patients not receiving any treatment. Survival was significantly improved in patients treated with TACE compared to those not treated with TACE (median survival: 14.5 months-TACE vs. 4.2 months-no treatment, p<0.001).